Evidence map›Paper›PMID 37334513›Full record

ArticleThe Korean journal of internal medicine2023

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

Soo-Kyung Cho, Hyoungyoung Kim, Yeo-Jin Song, Hye Won Kim, Eunwoo Nam, Shin-Seok Lee, Hye-Soon Lee, Sung-Hoon Park, Yeon-Ah Lee, Min-Chan Park and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 15 institutions in 3 countries.

Soo-Kyung ChoDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Seoul, Korea.
Hyoungyoung KimDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Seoul, Korea.
Yeo-Jin SongDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Seoul, Korea.
Hye Won KimDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Seoul, Korea.
Eunwoo NamDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Seoul, Korea.
Shin-Seok LeeDivision of Rheumatology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.
Hye-Soon LeeDepartment of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea.
Sung-Hoon ParkDivision of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Yeon-Ah LeeDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Kyung Hee University, Seoul, Korea.
Min-Chan ParkDivision of Rheumatology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Sung Hae ChangDivision of Rheumatology, Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
Hyoun-Ah KimDepartment of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
Seung-Ki KwokDivision of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hae-Rim KimDivision of Rheumatology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
Hyun-Sook KimDivision of Rheumatology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
Bo Young YoonDivision of Rheumatology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
Wan-Sik UhmUhm's Rheumatism Clinic, Seoul, Korea.
Yong-Gil KimDivision of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jae Hoon KimDivision of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Jisoo LeeDivision of Rheumatology, Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
Jeongim ChoiDivision of Rheumatology, Department of Internal Medicine, Busan Saint Mary's Hospital, Busan, Korea.
Yoon-Kyoung SungDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Seoul, Korea.
Konkuk University · KRHanyang University Seoul Hospital · KRChonnam National University Hospital · KRDaegu Catholic University · KREwha Womans University · KRHanyang University Guri Hospital · KRInje University Ilsan Paik Hospital · KRKorea University · KRKyung Hee University · KRSoonchunhyang University · KRSt. Mary's Medical Center · USSwedish Rheumatism Association · SEThe Catholic University of Korea Seoul St. Mary's Hospital · KRUlsan College · KRYonsei University · KR

Funding

Ministry of Health and Welfare HC19C0052Ministry of Health and Welfare HI19C0481Patient-Centered Clinical Research Coordinating Center
6 · The paper itself

Abstract

BACKGROUND/

aimsWe aimed to compare the effectiveness and safety of Janus kinase inhibitors (JAKi) vs. biologic disease- modifying antirheumatic drugs (bDMARD) in Korean patients with rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic DMARDs.

methodsA quasi-experimental, multi-center, prospective, non-randomized study was conducted to compare response rates between JAKi and bDMARDs in patients with RA naïve to targeted therapy. An interim analysis was performed to estimate the proportion of patients achieving low disease activity (LDA) based on disease activity score (DAS)-28- erythroid sedimentation rate (ESR) (DAS28-ESR) at 24 weeks after treatment initiation and to evaluate the development of adverse events (AEs).

resultsAmong 506 patients enrolled from 17 institutions between April 2020 and August 2022, 346 (196 JAKi group and 150 bDMARD group) were included in the analysis. After 24 weeks of treatment, 49.0% of JAKi users and 48.7% of bDMARD users achieved LDA (p = 0.954). DAS28-ESR remission rates were also comparable between JAKi and bDMARD users (30.1% and 31.3%, respectively; p = 0.806). The frequency of AEs reported in the JAKi group was numerically higher than that in the bDMARDs group, but the frequencies of serious and severe AEs were comparable between the groups.

conclusionOur interim findings reveal JAKi have comparable effectiveness and safety to bDMARDs at 24 weeks after treatment initiation.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiological ProductsJanus Kinase InhibitorsDrug Therapy, CombinationHumansProspective StudiesAntirheumatic AgentsBiological ProductsJanus Kinase InhibitorsComparative effectiveness researchJanus kinase inhibitorRheumatoid arthritisSafetyTumor necrosis factor inhibitors

Identifiers

PMID37334513
PMCPMC10338257
OpenAlexW4381158233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.